Freeze and burn: new device targets lung cancer during bronchoscopy

NCT ID NCT07398027

Not yet recruiting Disease control Sponsor: Carolin Steinack Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a device called the HybridTherm® system, which uses freezing and radiofrequency heat to destroy small lung tumors during a routine bronchoscopy. The procedure is done before the patient's planned surgery to remove the tumor. The main goals are to see if the device works as intended and to check for any serious bleeding. Only 20 people with early-stage lung cancer will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HybridTherm® System (device that combines freezing and radiofrequency heat to destroy tumors)
What this could lead to: If successful, this could provide a less invasive way to treat small lung tumors, potentially reducing the need for more extensive surgery.
What could go wrong: This is a very early, small study (20 people) focused on feasibility, not effectiveness. The procedure carries risks like bleeding, and it's unknown if it will work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

University Hospital Zurich

Zurich, Raemistrasse, 8091, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.